Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13206684 | 0.90 | THRA (0.46) | THRATHRBPTGDR2AKR1B1KDM4E | |
| SCHEMBL1757820 | 0.85 | RAB9A (0.60) | THRATHRBKDM4ELMNAALDH1A1 | |
| SCHEMBL27847165 | 0.83 | KDM4E (0.47) | THRATHRBPTGDR2AKR1B1KDM4E | |
| SCHEMBL15047970 | 0.83 | THRA (0.44) | THRATHRBPTGDR2AKR1B1KDM4E | |
| SCHEMBL3561181 | 0.82 | PTGDR2 (0.53) | THRATHRBPTGDR2AKR1B1KDM4E | |
| SCHEMBL28815311 | 0.80 | KDM4E (0.57) | PTGDR2AKR1B1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL2988492 | 0.77 | KDM4E (0.51) | THRBPTGDR2AKR1B1KDM4ELMNA | |
| SCHEMBL2979855 | 0.76 | CCR2 (0.52) | KDM4ELMNASMN1; SMN2GLAALDH1A1 | |
| SCHEMBL3763223 | 0.76 | GAA (0.49) | PTGDR2AKR1B1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL1055122 | 0.75 | POLB (0.42) | THRATHRBKDM4EALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451780-B1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4-(ACETYLAMINO))-3-[(4-CHLORO-PHENYL)THIO]-2-METHYL-1H-INDOLE-1-ACETIC ACID | ASTRAZENECA AB (SE) | 2013-06-19 | — | — | EP | disclosed |
| EP-2451780-B1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4-(ACETYLAMINO))-3-[(4-CHLORO-PHENYL)THIO]-2-METHYL-1H-INDOLE-1-ACETIC ACID | ASTRAZENECA AB (SE) | 2013-06-19 | — | — | EP | disclosed |
| US-8227622-B2 | Pharmaceutical process and intermediates 714 | ASTRAZENECA AB (SE) | 2012-07-24 | — | — | US | disclosed |
| US-8227622-B2 | Pharmaceutical process and intermediates 714 | ASTRAZENECA AB (SE) | 2012-07-24 | — | — | US | disclosed |
| US-8227622-B2 | Pharmaceutical process and intermediates 714 | ASTRAZENECA AB (SE) | 2012-07-24 | — | — | US | disclosed |
| US-20120178764-A1 | Novel Compounds | BONNERT ROGER (GB) | 2012-07-12 | — | — | US | disclosed |
| EP-2451780-A1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4- (ACETYLAMINO) ) -3- [ (4-CHLORO-PHENYL) THIO]-2-METHYL-1H-INDOLE-1-ACETIC ACID | AstraZeneca AB (SE) | 2012-05-16 | — | — | EP | disclosed |
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| US-7781598-B2 | Process for the preparation of substituted indoles | ASTRAZENECA AB (SE) | 2010-08-24 | — | — | US | disclosed |
| US-7687535-B2 | Substituted 3-sulfur indoles | ASTRAZENECA AB (SE) | 2010-03-30 | — | — | US | disclosed |
| US-20090163518-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
| EP-2025670-A1 | 3-(Phenyl or quinolyl)thio-1H-indole-1-acetic acid derivatives as modulators of CRTh2 receptor activity | AstraZeneca AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-20080249110-A1 | Novel Substituted 3-Sulfur Indoles | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | US | disclosed |
| US-20080051586-A1 | Novel Process for the Preparation of Substituted Indoles | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051586-A1 | Novel Process for the Preparation of Substituted Indoles | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051586-A1 | Novel Process for the Preparation of Substituted Indoles | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| EP-1844012-A2 | NOVEL PROCESS FOR THE PREPARATION OF SUBSTITUTED INDOLES | AstraZeneca AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006075139-A2 | NOVEL PROCESS FOR THE PREPARATION OF SUBSTITUTED INDOLES | ASTRAZENECA AB (SE) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | CYP3A4, CYP4A11, CYP4B1 | THRA 2549/4885THRB 2833/4885PTGDR2 3430/4885 |
| US-20080051586-A1 | Novel Process for the Preparation of Substituted Indoles | IDO1, IDO2, TPH1 | THRA 3479/4885THRB 2726/4885PTGDR2 390/4885 |
| US-20120178764-A1 | Novel Compounds | IDO1, IDO2, MTNR1A | THRA 2266/4885THRB 1196/4885PTGDR2 227/4885 |
| US-20090163518-A1 | Novel Compounds | IDO1, IDO2, MTNR1A | THRA 2266/4885THRB 1196/4885PTGDR2 227/4885 |
| US-20080249110-A1 | Novel Substituted 3-Sulfur Indoles | IDO1, IDO2, AANAT | THRA 2079/4885THRB 1057/4885PTGDR2 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.